Skip to main content

Precision Biosciences Inc

DTIL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001357874

No open-market purchases or sales by Precision Biosciences Inc insiders were filed in the last 90 days; 95 institutions reported holding it in 13F filings for Q2 2026, worth $138.9M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Precision Biosciences Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Precision Biosciences Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Precision Biosciences Inc
NameTitleLast reported holdingLast filingFilings, past year
Germano Geno JDirector44,883Jun 5, 20263
Brown MelindaDirector44,346Jun 5, 20263
Buehler KevinDirector49,137Jun 5, 20262
Frankel StanleyDirector40,478Jun 5, 20264
Pire Shari LisaDirector35,028Jun 5, 20262
Kelly John AlexanderChief Financial Officer125,883Jun 3, 20264
Smith J. JeffersonChief Research Officer121,926Jun 3, 20263
Scimeca DarioGeneral Counsel and Secretary56,457Jun 3, 20264
Amoroso MichaelPresident and CEO243,392Jun 3, 20264
Wadsworth Samuel C.Director4,202Jun 6, 20240
List AlanChief Medical Officer4,488May 3, 20240
Barton ShaneVP & Corporate Controller27,502Jun 9, 20230
Jantz DerekChief Scientific Officer4,055,174Jun 9, 20220
Schinazi Raymond FDirector–May 12, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 19, 2026 (view filing)Feb 181 dayAmoroso MichaelPresident and CEOSSale−20.6K$3.84−$78.9K−7.8%243.4K after10b5-1
Feb 19, 2026 (view filing)Feb 181 dayKelly John AlexanderChief Financial OfficerSSale−8.15K$3.84−$31.3K−6.1%125.9K after10b5-1
Feb 19, 2026 (view filing)Feb 181 dayScimeca DarioGeneral Counsel and SecretarySSale−4.92K$3.84−$18.9K−8.0%56.5K after10b5-1
Feb 19, 2026 (view filing)Feb 181 daySmith J. JeffersonChief Research OfficerSSale−4.92K$3.84−$18.9K−3.9%121.9K after10b5-1
Jan 22, 2026 (view filing)Jan 22Same dayAmoroso MichaelPresident and CEOSSale−34.8K$4.17−$145.1K−15.1%196.2K after10b5-1
Jan 22, 2026 (view filing)Jan 211 dayScimeca DarioGeneral Counsel and SecretarySSale−8.85K$4.03−$35.7K−16.5%44.7K after10b5-1
Jan 22, 2026 (view filing)Jan 211 dayKelly John AlexanderChief Financial OfficerSSale−15.2K$4.03−$61.3K−12.5%106.4K after10b5-1
Jan 22, 2026 (view filing)Jan 211 daySmith J. JeffersonChief Research OfficerSSale−10.2K$4.03−$41.1K−8.5%110.2K after10b5-1
Dec 17, 2025 (view filing)Dec 161 dayGermano Geno JDirectorPPurchase+3.00K$4.72+$14.2K+14.4%23.9K after
Dec 17, 2025 (view filing)Dec 161 dayFrankel StanleyDirectorPPurchase+2.70K$4.70+$12.7K+16.1%19.5K after
Dec 17, 2025 (view filing)Dec 152 daysBrown MelindaDirectorPPurchase+1.38K$4.97+$6.86K+6.3%23.3K after
Nov 4, 2025 (view filing)Nov 31 dayKelly John AlexanderChief Financial OfficerSSale−1.30K$6.49−$8.46K−1.7%77.3K after10b5-1
Nov 4, 2025 (view filing)Nov 31 dayScimeca DarioGeneral Counsel and SecretarySSale−665$6.49−$4.32K−2.3%28.3K after10b5-1
Nov 4, 2025 (view filing)Nov 31 dayAmoroso MichaelPresident and CEOSSale−3.41K$6.49−$22.1K−2.9%115.6K after10b5-1
Sep 30, 2025 (view filing)Sep 264 daysFrankel StanleyDirectorPPurchase+2.70K$4.97+$13.4K+19.2%16.8K after
Sep 24, 2025 (view filing)Sep 222 daysBrown MelindaDirectorPPurchase+1.40K$4.89+$6.85K+6.8%22.0K after
Jul 8, 2025 (view filing)Jul 35 daysKelly John AlexanderChief Financial OfficerSSale−14.8K$4.26−$63.2K−16.8%73.5K after10b5-1
Jun 27, 2025 (view filing)Jun 252 daysBrown MelindaDirectorPPurchase+1.68K$4.14+$6.96K+8.9%20.6K after
Jun 27, 2025 (view filing)Jun 252 daysBuehler KevinDirectorPPurchase+5.08K$4.16+$21.1K+22.0%28.1K after
Mar 28, 2025 (view filing)Mar 262 daysBrown MelindaDirectorPPurchase+1.84K$4.75+$8.74K+25.5%9.06K after
Mar 28, 2025 (view filing)Mar 262 daysBuehler KevinDirectorPPurchase+4.52K$4.67+$21.1K+51.9%13.2K after
Mar 27, 2025 (view filing)Mar 252 daysGermano Geno JDirectorPPurchase+3.25K$5.30+$17.2K+41.6%11.1K after
Mar 25, 2025 (view filing)Mar 241 dayAmoroso MichaelPresident and CEOSSale−964$5.56−$5.36K−0.9%109.5K after10b5-1
Mar 5, 2025 (view filing)Mar 41 dayScimeca DarioGeneral Counsel and SecretarySSale−272$4.91−$1.34K−1.1%25.0K after10b5-1
Mar 5, 2025 (view filing)Mar 41 daySmith J. JeffersonChief Research OfficerSSale−154$4.91−$756.14−0.2%87.8K after10b5-1
Jan 22, 2025 (view filing)Jan 22Same dayScimeca DarioGeneral Counsel and SecretarySSale−8.93K$4.79−$42.8K−26.8%24.4K after10b5-1
Jan 22, 2025 (view filing)Jan 211 dayAmoroso MichaelPresident and CEOSSale−36.8K$4.67−$172.0K−25.6%107.1K after10b5-1
Jan 22, 2025 (view filing)Jan 22Same daySmith J. JeffersonChief Research OfficerSSale−10.3K$4.79−$49.3K−10.5%87.4K after10b5-1
Jan 2, 2025 (view filing)Dec 30, 20243 daysGermano Geno JDirectorPPurchase+3.60K$4.49+$16.2K+85.8%7.81K after
Dec 31, 2024 (view filing)Dec 274 daysBuehler KevinDirectorPPurchase+4.32K$4.88+$21.1K+98.4%8.71K after
Dec 31, 2024 (view filing)Dec 274 daysKelly John AlexanderChief Financial OfficerPPurchase+2.11K$4.75+$10.0K+5.5%40.2K after
Dec 30, 2024 (view filing)Dec 264 daysBrown MelindaDirectorPPurchase+3.02K$4.55+$13.7K+71.8%7.22K after
Nov 21, 2024 (view filing)Nov 21Same dayKelly John AlexanderChief Financial OfficerPPurchase+3.00K$6.76+$20.3K+8.6%38.1K after
Nov 5, 2024 (view filing)Nov 41 dayScimeca DarioGeneral Counsel and SecretarySSale−588$8.19−$4.82K−6.9%7.97K after10b5-1
Nov 5, 2024 (view filing)Nov 41 dayAmoroso MichaelPresident and CEOSSale−3.01K$8.19−$24.7K−9.5%28.5K after
Jun 11, 2024 (view filing)Jun 101 dayScimeca DarioGeneral Counsel and SecretarySSale−93$11.79−$1.10K−1.4%6.72K after10b5-1
Jun 11, 2024 (view filing)Jun 101 daySmith J. JeffersonChief Research OfficerSSale−50$11.79−$589.5−0.1%68.6K after
May 3, 2024 (view filing)May 21 dayScimeca DarioGeneral Counsel and SecretarySSale−272$10.32−$2.81K−4.6%5.68K after10b5-1
May 3, 2024 (view filing)May 12 daysScimeca DarioGeneral Counsel and SecretarySSale−918$0.00$0–919 afterDerivative10b5-1
May 3, 2024 (view filing)May 21 daySmith J. JeffersonChief Research OfficerSSale−154$10.32−$1.59K−0.2%67.6K after
May 3, 2024 (view filing)May 21 dayList AlanChief Medical OfficerSSale−290$10.32−$2.99K−6.1%4.49K after
May 3, 2024 (view filing)May 21 dayAmoroso MichaelPresident and CEOSSale−1.53K$10.32−$15.7K−10.0%13.8K after
Apr 30, 2024 (view filing)Apr 30Same dayList AlanChief Medical OfficerSSale−238$10.03−$2.39K−5.9%3.80K after
Jan 23, 2024 (view filing)7:17 PM ETJan 221 dayAmoroso MichaelPresident and CEOSSale−137.4K$0.36−$49.5K−27.8%356.4K after10b5-1
Jan 23, 2024 (view filing)7:15 PM ETJan 221 dayScimeca DarioGeneral Counsel and SecretarySSale−21.3K$0.36−$7.66K−12.4%151.0K after10b5-1
Jan 23, 2024 (view filing)7:13 PM ETJan 221 dayList AlanChief Medical OfficerSSale−21.5K$0.36−$7.75K−18.5%95.0K after10b5-1
Jan 23, 2024 (view filing)7:11 PM ETJan 23Same daySmith J. JeffersonChief Research OfficerSSale−28.0K$0.37−$10.4K−1.4%1.99M after
Nov 6, 2023 (view filing)5:09 PM ETNov 33 daysScimeca DarioGeneral Counsel and SecretarySSale−16.0K$0.40−$6.41K−12.4%113.0K after10b5-1
Nov 6, 2023 (view filing)5:07 PM ETNov 33 daysAmoroso MichaelPresident and CEOSSale−125.0K$0.40−$50.0K−35.5%227.1K after10b5-1
Oct 27, 2023 (view filing)4:55 PM ETAug 1870 daysKelly John AlexanderChief Financial OfficerPPurchase+90.0K$0.48+$43.2K+30.7%383.3K afterAmended